Status:
UNKNOWN
Long-term Outcomes After Conversion to Belatacept
Lead Sponsor:
Paris Translational Research Center for Organ Transplantation
Conditions:
Kidney Transplant Failure and Rejection
Immunosuppression
Eligibility:
All Genders
18+ years
Brief Summary
belatacept is a selective T-cell co-stimulation blocker that was approved by Food and Drug Administration (FDA) in 2011 for the prophylaxis of graft rejection in adult kidney transplant recipients. Th...
Detailed Description
belatacept is a selective T-cell co-stimulation blocker that was approved by Food and Drug Administration (FDA) in 2011 for the prophylaxis of graft rejection in adult kidney transplant recipients. Th...
Eligibility Criteria
Inclusion
- Male or Female, over 18 years of age
- Recipient of kidney allograft from a living donor or a deceased donor
Exclusion
- Graft loss during the first three months post-transplant
- Epstein-Barr virus Seronegative in the belatacept group
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
324 Patients enrolled
Trial Details
Trial ID
NCT04733131
Start Date
January 1 2004
End Date
December 1 2021
Last Update
February 1 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.